BioCryst Pharmaceuticals Management
Management criteria checks 1/4
BioCryst Pharmaceuticals' CEO is Charlie Gayer, appointed in Aug 2025, has a tenure of less than a year. total yearly compensation is $9.63M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth MX$60.48M. The average tenure of the management team and the board of directors is 1 years and 4.8 years respectively.
Key information
Charlie Gayer
Chief executive officer
US$9.6m
Total compensation
| CEO salary percentage | 6.33% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 1yr |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$458m |
| Dec 31 2025 | US$10m | US$609k | US$264m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$53m |
| Dec 31 2024 | US$3m | US$545k | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$146m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$2m | US$495k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$2m | US$449k | -US$247m |
Compensation vs Market: Charlie's total compensation ($USD9.63M) is above average for companies of similar size in the MX market ($USD1.67M).
Compensation vs Earnings: Charlie's compensation has increased whilst the company is unprofitable.
CEO
Charlie Gayer (55 yo)
Mr. Charles K. Gayer, also known as Charlie, is President at BioCryst Pharmaceuticals, Inc. since August 1, 2025 and serves as its Chief Executive Officer & Director since January 01, 2026. He served as th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$9.63m | 0.14% MX$ 60.5m | |
| CFO & Head of Corporate Development | 1yr | US$6.75m | no data | |
| Senior VP | 19.8yrs | US$5.62m | 0.058% MX$ 24.5m | |
| Chief Technical Operations Officer | less than a year | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Manager of Investor Relations | no data | no data | no data | |
| Chief People Officer & Chief Communications Officer | less than a year | no data | no data | |
| Chief Development Officer | 18yrs | US$2.66m | no data | |
| Chief Discovery Officer | 12.8yrs | US$2.57m | no data | |
| Chief Data Innovation Officer | 4.7yrs | no data | no data | |
| Chief Strategy Officer | 3.8yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | 0.020% MX$ 8.6m |
Experienced Management: BCRX *'s management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$9.63m | 0.14% MX$ 60.5m | |
| Independent Chairman | 5yrs | US$403.70k | 0.032% MX$ 13.4m | |
| Independent Director | 6.4yrs | US$397.50k | 0.020% MX$ 8.6m | |
| Independent Director | 1.2yrs | US$396.49k | 0.0025% MX$ 1.1m | |
| Independent Director | less than a year | no data | 0.0017% MX$ 725.1k | |
| Independent Director | 7.6yrs | US$401.70k | 0.021% MX$ 8.8m | |
| Director | 19.5yrs | US$12.95m | 0.41% MX$ 172.0m | |
| Independent Director | 4.8yrs | US$385.58k | 0.023% MX$ 9.7m | |
| Independent Director | 4.4yrs | US$385.25k | 0.0071% MX$ 3.0m | |
| Independent Director | 4.8yrs | US$390.00k | 0.0076% MX$ 3.2m |
Experienced Board: BCRX *'s board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 07:13 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCryst Pharmaceuticals, Inc. is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |